整形与重建外科随机对照试验质量分析
该综述评估了2013至2022年发表于Plastic and Reconstructive Surgery的146项随机对照试验的方法学与报告质量。平均Jadad评分为2.96±1.21,平均偏倚风险评分为5.65±2.14,提示中等方法学质量;手术技术或医疗器械试验的方法学质量较药物干预差,乳腺试验方法学评分最高但随时间下降;近半数试验未明确报告主要结局或分析集,整体报告标准欠佳,未观察到显著时间趋势。
要点
- 2013至2022年PRS发表的146项RCT方法学质量中等,平均Jadad评分2.96±1.21。
- 手术技术或医疗器械试验的方法学质量较药物干预差。
- 乳腺试验方法学评分最高但随时间下降;近半数未明确报告主要结局或分析集。
核心结论
- 2013至2022年发表于PRS的RCT方法学质量中等,整体报告标准欠佳,未观察到显著时间趋势。
研究设计与样本
- 对2013至2022年发表于Plastic and Reconstructive Surgery的RCT进行综述,共纳入146项RCT,使用Jadad评分和改良Cochrane偏倚风险工具评估方法学质量,并收集数据评估报告质量、方法学质量预测因素及时间趋势。
主要发现
- 146项RCT的平均Jadad评分为2.96±1.21,平均偏倚风险评分为5.65±2.14,提示中等方法学质量。
- 评估手术技术或医疗器械的试验与药物干预相比方法学质量更差。
- 乳腺试验的方法学评分最高之一,但该评分随时间下降。
- 整体报告标准欠佳,近半数试验未能明确陈述主要结局或分析集。
- 未观察到显著的时间趋势。
关键数值与推荐
- 平均Jadad评分2.96±1.21(146项RCT)。
- 平均偏倚风险评分5.65±2.14(146项RCT)。
- 近半数试验未明确陈述主要结局或分析集。
临床怎么用
- 作者指出,研究结果强调透明报告和方法学严谨性对推进整形外科循证实践的重要性;通过遵循既定方法学标准和报告指南,研究者可提高研究的可靠性和影响力。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assessing the methodologic and reporting quality of randomized controlled trials (RCTs) in plastic surgery is crucial in maintaining the standards of evidence-based practice. Previous evaluations underscored deficiencies in reporting and methodology, prompting a call for improvement. This review scrutinizes the methodologic and reporting standards of RCTs published in Plastic and Reconstructive Surgery (PRS) from 2013 to 2022. METHODS: The authors conducted a review of RCTs published in PRS from 2013 to 2022. Methodologic quality of RCTs was assessed using the Jadad score and a modified Cochrane risk-of-bias tool. Additional relevant data were gathered to assess reporting quality, ascertain predictors of methodologic quality, and identify temporal trends. RESULTS: A total of 146 RCTs were reviewed. The mean Jadad score was 2.96 ± 1.21, and the average risk-of-bias score was 5.65 ± 2.14, indicating moderate methodologic quality. Trials assessing surgical techniques or medical devices were associated with poorer methodologic quality compared with drug interventions. Breast trials showed one of the highest methodologic scores, but this declined over time. Overall reporting standards were suboptimal, with nearly half of the trials failing to explicitly state primary outcomes or analysis sets. No significant temporal trends were observed. CONCLUSIONS: RCTs published in PRS between 2013 and 2022 exhibited moderate methodologic quality. The authors' findings underscore the importance of transparent reporting and methodologic rigor in advancing evidence-based practices in plastic surgery. By adhering to established methodologic standards and reporting guidelines, researchers can enhance the reliability and impact of their studies.
引用
- Wong GC, Cullen CM, Kim HM, et al. A Critical Analysis of Randomized Controlled Trial Quality in Plastic and Reconstructive Surgery. Plast Reconstr Surg. 2024. PMID: 40561451. doi:10.1097/PRS.0000000000011864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。